Mr. Haussler et al., NEW UNDERSTANDING OF THE MOLECULAR MECHANISM OF RECEPTOR-MEDIATED GENOMIC ACTIONS OF THE VITAMIN-D HORMONE, Bone, 17(2), 1995, pp. 33-38
The nuclear vitamin D receptor (VDR) binds the 1,25-dihydroxyvitamin D
-3 [1,25(OH)(2)D-3] hormone with high affinity and elicits its actions
to regulate gene expression in target cells by binding to vitamin D-r
esponsive elements (VDREs), VDREs in positively controlled genes such
as osteocalcin, osteopontin, beta(3)-integrin, and vitamin D-24-OHase
are direct hexanucleotide repeats with a spacer of three nucleotides,
The VDR associates with these VDREs with the greatest affinity as a he
terodimer with one of the family of retinoid X receptors (RXRs), VDR c
onsists of an N-terminal zinc finger domain that determines DNA bindin
g, a ''hinge'' segment and a C-terminal hormone binding domain which a
lso contains two conserved regions that engage in heterodimerization w
ith an RXR on the VDRE, The role of the 1,25(OH)(2)D-3 ligand in trans
criptional activation by the VDR-RXR heterodimer is to alter the confo
rmation of the hormone-binding domain of VDR to facilitate strong dime
rization with RXR, which results in ligand-enhanced association with t
he VDRE, Thus RXR is recruited into a heterocomplex by liganded VDR, T
he natural ligand for the RXR coreceptor, 9-cis retinoic acid, suppres
ses both VDR-RXR binding to the VDRE and 1,25(OH)(2)D-3-stimulated tra
nscription, indicating that 9-cis retinoic acid diverts RXR away from
being the silent partner of VDR to instead form RXR homodimers, Recent
data reveal that after binding RXR, a subsequent target for VDR in th
e vitamin D signal transduction cascade is basal transcription factor
IIB (TFIIB), VDR can be shown to bind directly to TFIIB, in vitro, and
synergizes with it in transcriptional control by 1,25(OH)(2)D-3 in tr
ansfected cells, thus unveiling a molecular mechanism whereby 1,25(OH)
(2)D-3 activates the transcription machine, Finally, natural mutations
in hVDR that confer 1,25(OH)(2)D-3 resistance in a number of patients
have been characterized, The mutations fall into three categories: (i
) DNA binding/nuclear localization; (ii) hormone binding; and (iii) RX
R heterodimerization, These natural mutations are consistent with the
structure/function analysis of hVDR via biochemical and molecular biol
ogical approaches and confirm the basic model of the receptor as a DNA
-bound active heterodimer of liganded hVDR and unoccupied RXR.